Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of KQ-791 in Subjects With Type 2 Diabetes
Phase of Trial: Phase I
Latest Information Update: 19 Sep 2016
At a glance
- Drugs KQ 791 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Sponsors Kaneq Bioscience
- 10 Jun 2017 Biomarkers information updated
- 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 25 Nov 2015 Planned end date changed from 1 Jan 2016 to 1 Mar 2016, as reported by ClinicalTrials.gov.